HUTCHMED (LON:HCM) Share Price Passes Below 200-Day Moving Average of $222.08

Shares of HUTCHMED (China) Limited (LON:HCMGet Rating) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 222.08 ($2.68) and traded as low as GBX 162.40 ($1.96). HUTCHMED shares last traded at GBX 162.40 ($1.96), with a volume of 54,536 shares changing hands.

Analyst Ratings Changes

A number of research analysts recently weighed in on HCM shares. Barclays reissued an “equal weight” rating and issued a GBX 100 ($1.21) target price on shares of HUTCHMED in a report on Tuesday, July 19th. Citigroup reissued a “buy” rating and issued a GBX 220 ($2.66) target price on shares of HUTCHMED in a report on Thursday, June 23rd.

HUTCHMED Stock Performance

The stock has a market capitalization of £1.40 billion and a PE ratio of -8.08. The business’s fifty day moving average is GBX 214.17 and its two-hundred day moving average is GBX 222.08. The company has a quick ratio of 2.97, a current ratio of 3.18 and a debt-to-equity ratio of 0.05.

About HUTCHMED

(Get Rating)

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.

Recommended Stories

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.